Search Results

Aldevron, a leading global manufacturer of DNA, RNA, and proteins used in cell and gene therapies and vaccine development, today announced it has entered a strategic partnership with Acuitas Therapeutics, Inc., a private biotechnology company specializing in the development of delivery systems for nucleic acid therapeutics based on lipid nanoparticles (LNPs).

Codexis, Inc. announced it has entered into an agreement with Aldevron, a global leader in the custom development and manufacture of plasmid DNA, RNA and proteins for the biotech industry, whereby Aldevron will acquire a global exclusive license to Codexis’ Codex® HiCap RNA Polymerase.

Jennifer Meade has been named President of Aldevron, effective September 11th 2023, as part of a planned leadership transition.

Integrated DNA Technologies and Aldevron® Activate Strategic Partnership to Deliver Key CRISPR Components to Cell and Gene Therapy Developers.

Aldevron contributed to a publication in collaboration with 2020 Nobel Laureate Jennifer Doudna and the Innovative Genomics Institute (IGI) at the University of California, Berkeley to advance research on in vivo, CRISPR-based genome editing strategies to address genetic diseases of the central nervous system such as Huntington’s disease and ALS.

Evanoa Bioscience Inc., a cell line developer for biologics manufacturing, together with Aldevron®, a global leader in the custom development and manufacture of plasmid DNA, RNA and proteins for the biotech industry, announced the signing of a licensing agreement for two E. coli strains to be used in plasmid production.

Aldevron®, a global leader in the custom development and manufacture of plasmid DNA, RNA and proteins for the biotech industry, launches Eureca-V™ Nuclease, the wild-type MAD7® CRISPR Type-V nuclease, licensed from Inscripta®, at Research Grade today with GMP to follow.

Danaher Corporation (NYSE: DHR) (the “Company”) announced today that Danaher has entered into a definitive agreement to acquire privately-held Aldevron, for a cash purchase price of approximately $9.6 billion.

Months after landing a massive SPAC deal that carried Ginkgo Bioworks to the Nasdaq, the company is now touting a manufacturing breakthrough from partner Aldevron for mRNA vaccine components.

Aruvant Sciences and Aldevron announced that Aldevron will support the development of ARU-1801, Aruvant’s one-time investigational gene therapy for sickle cell disease, and ARU-2801, a one-time investigational gene therapy for hypophosphatasia.